Skip to main content
Journal of Diabetes Investigation logoLink to Journal of Diabetes Investigation
. 2018 Sep 4;9(5):1233. doi: 10.1111/jdi.12885

Erratum

PMCID: PMC6123023  PMID: 30180306

The authors would like to draw the reader's attention to the error in the following article.

Yan WJ, Sun P, Wei DD, Wang SX, Yang JJ, Li YH, Zhang C. T cell immunoglobulin and mucin domain‐containing molecule 3 on CD14+ monocytes serves as a novel biological marker for diabetes duration in type 2 diabetes mellitus. J Diabetes Investig 2016; 7: 867–873.

On page 869, CD14+ T cells should have been replaced with CD14+ monocytes cells to read as follows in the legend of Figure 1.

Figure 1 | T cell immunoglobulin and mucin domain‐containing molecule 3 (Tim‐3) expression on CD14+ monocytes cells in type 2 diabetes patients is significantly decreased. Peripheral blood mononuclear cells were isolated from healthy donors (n = 18) and patients with type 2 diabetes (n = 31). (a) Flow cytometry analysis of Tim‐3 expression on CD14+ monocytes cells (left) and the statistical graph is shown (right) for type 2 diabetes patients (n = 31, 30.43 ± 3.58%) and healthy donors (n = 18, 50.78 ± 2.36%). (b) Correlation analysis of Tim‐3 expression on CD14+ monocytes cells and type 2 diabetes patients’ fasting plasma glucose (FPG), glycated hemoglobin (HbA1c), insulin, body mass index (BMI), age and diabetes duration. ***P < 0.001.

The authors apologize for the error and any confusion it may have caused.


Articles from Journal of Diabetes Investigation are provided here courtesy of Wiley

RESOURCES